作者:Xiao-Guang Bai、Chang-Liang Xu、Shuang-Shuang Zhao、Hong-Wei He、Yu-Cheng Wang、Ju-Xian Wang
DOI:10.3390/molecules191117256
日期:——
A series of chalcones a1–20 bearing a 4-OMe groups on the A-ring were initially synthesized and their anticancer activities towards HepG2 cells evaluated. Subsequently, a series of chalcones b1–42 bearing methoxy groups at the 2' and 6'-positions of the B-ring were synthesized and their anticancer activities towards five human cancer cell lines (HepG2, HeLa, MCF-7, A549 and SW1990) and two non-tumoral human cell lines evaluated. The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines. Compound b29 showed a promising SI value compared with both HMLE and L02 (2.1–6.5 fold in HMLE and > 33 > 103.1 fold in L02, respectively).
一系列在A环上带有4-OMe基团查尔酮a1-20被合成,并评估了它们对HepG2细胞的抗癌活性。随后,合成了一系列在B环的2'和6'-位置带有甲氧基的查尔酮b1-42,并评估了它们对五种人癌细胞系(HepG2、HeLa、MCF-7、A549和SW1990)和两种非瘤人细胞系的抗癌活性。结果显示,六个化合物(b6、b8、b11、b16、b18、b22、b23和b29)显示出有望的活性,特别是化合物b22和b29在所有五种癌细胞系中显示出比依托泊苷更高的活性水平。与HMLE和L02相比,化合物b29显示出有希望的SI值(分别是HMLE的2.1-6.5倍,L02的>103.1倍)。